Clinical trials
Terminated Hemoglobinopathies trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2005 | 1 |
| 2009 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 12 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bellicum Pharmaceuticals | 3 |
| Baylor College of Medicine | 2 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Craig Seaman | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 1 |
| University of California, San Francisco | 1 |
| Wake Forest University Health Sciences | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemoglobinopathies | 12 |
| Anemia, Sickle Cell | 9 |
| Thalassemia | 7 |
| Anemia | 4 |
| Anemia, Diamond-Blackfan | 3 |
| Fanconi Anemia | 3 |
| Leukemia, Myeloid, Acute | 3 |
| Myelodysplastic Syndromes | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Primary Immunodeficiency Diseases | 3 |
Trials
Showing 51 to 12 of 12. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.